Skip to content

GMAB

Genmab A/S

NASDAQ · Healthcare · Biotechnology · DK

$34.74
+0.59%
Ask drillr

Next report

Analyst consensus

Next report date
Nov 5, 2026
EPS estimate
$0.37
Revenue estimate
$1.2B

Latest reported

Last report date
Aug 6, 2026
EPS actual
$0.54
EPS estimate
$0.37
Revenue actual
$1.2B
Revenue estimate
$1.1B

Track record

Trailing twelve quarters

EPS beats (12Q)
6
EPS misses (12Q)
4
EPS in line (12Q)
2
Avg surprise (4Q)
-1.9%
Revenue beats (12Q)
9

Analyst ratings

Sell-side consensus

Consensus
Buy
Price target
$42
PT range
$40 – $43
Analysts
3
3 Buy0 Hold0 Sell
Reported history
Report dateEPS estimateEPS actualSurpriseRevenue actual
Aug 6, 2026$0.37$0.54Beat 45.95%$1.2B
May 7, 2026$0.15$0.15In line$896.0M
Feb 17, 2026$0.46$0.05Miss -89.13%$6.7B
Nov 6, 2025$0.48$0.65Beat 35.42%$1.0B
Aug 7, 2025$0.39$0.54Beat 38.46%$924.8M
May 8, 2025$0.23$0.31Beat 34.78%$726.0M
Feb 12, 2025$0.28$0.57Beat 103.57%$891.4M
Aug 8, 2024$0.29$0.22Miss -24.14%$777.8M
May 2, 2024$0.16$0.16In line$594.9M
Feb 14, 2024$0.34$0.36Beat 5.88%$690.3M
Aug 3, 2023$2.18$0.30Miss -86.24%$613.3M
Feb 22, 2023$3.15$0.12Miss -96.19%$755.0M

Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026